MARKET

HALO

HALO

Halozyme
NASDAQ

Real-time Quotes | Nasdaq Last Sale

54.94
+7.73
+16.37%
Opening 13:19 02/24 EST
OPEN
48.27
PREV CLOSE
47.21
HIGH
56.40
LOW
48.27
VOLUME
6.26M
TURNOVER
--
52 WEEK HIGH
56.40
52 WEEK LOW
12.71
MARKET CAP
7.43B
P/E (TTM)
358.15
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 23)
Benzinga · 5h ago
DJ Halozyme Therapeutics, Inc. CEO Helen Torley on Q4 2020 Results -- Earnings Call Transcript >HALO
Dow Jones · 15h ago
RCMT, PUBM, WAFD and HALO among after-hours movers
Gainers: [[RCMT]] +47.2%. [[UPWK]] +18.5%. [[PUBM]] +9.5%. [[HX]] +9.5%. [[WSFS]] +8.3%.Losers: [[WAFD]] -18.0%. [[XPER]] -8.8%. [[HALO]] -5.7%. [[ATRC]] -5.0%. [[SLDB]] -4.7%.
Seekingalpha · 19h ago
BRIEF-Halozyme Reports Proposed Offering Of $500 Mln Of Convertible Senior Notes Due 2027
reuters.com · 20h ago
BRIEF-Halozyme Reports Fourth Quarter 2020 Results
reuters.com · 20h ago
8-K: HALOZYME THERAPEUTICS, INC.
(EDGAR Online via COMTEX) -- false 0001159036 0001159036 2021-02-23 2021-02-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 20h ago
Halozyme Therapeutics: Plans to Buy Back Up to $125M in Common Stock in 2021 as Part of $550M 3-Yr Share-Repurchase Plan >HALO
Halozyme Therapeutics: Plans to Buy Back Up to $125M in Common Stock in 2021 as Part of $550M 3-Yr Share-Repurchase Plan >HALO
Dow Jones · 20h ago
Halozyme Therapeutics 4Q EPS $1.40 Vs. EPS $1.55 >HALO
Halozyme Therapeutics 4Q EPS $1.40 Vs. EPS $1.55 >HALO
Dow Jones · 21h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HALO. Analyze the recent business situations of Halozyme through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HALO stock price target is 45.82 with a high estimate of 65.00 and a low estimate of 17.00.
EPS
Institutional Holdings
Institutions: 470
Institutional Holdings: 151.26M
% Owned: 111.89%
Shares Outstanding: 135.18M
TypeInstitutionsShares
Increased
102
16.36M
New
119
1.98M
Decreased
102
16.28M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.64%
Pharmaceuticals & Medical Research
+1.36%
Key Executives
Chairman/Independent Director
Connie Matsui
President/Chief Executive Officer/Director
Helen Torley
Chief Financial Officer/Senior Vice President
Elaine Sun
Independent Director
Jean-Pierre Bizzari
Independent Director
Bernadette Connaughton
Independent Director
James Daly
Independent Director
Jeffrey Henderson
Independent Director
Kenneth Kelley
Independent Director
Matthew Posard
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About HALO
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Webull offers kinds of Halozyme Therapeutics, Inc. stock information, including NASDAQ:HALO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HALO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HALO stock methods without spending real money on the virtual paper trading platform.